Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and antibody drug conjugate (ADC)-based therapies, today announced that global oncology leader, Genmab has licensed a novel antibody related to one of OBT's IO programs. The target was discovered using Oxford BioTherapeutics' proprietary OGAP® drug discovery platform, which incorporates one of the world's largest proteomic databases, integrating clinical, experimental and expression data.
Under the terms of the agreement, Genmab will be responsible for the future development and commercialization of any products incorporating this antibody. In addition to the upfront payment, OBT will receive additional development and regulatory milestone payments as well as royalties on any future product sales. This represents the first major license agreement for OBT's IO programs to a world leader in the field of antibody-based oncology medicines.